Scribd Logo
Upload

Welcome to Scribd!

    • 73 views

    Glenmark Pharmaceuticals LTD

    Uploaded by

    Harshit Kumar Singh
    Glenmark Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company listed on both the Bombay Stock Exchange and National Stock Exchange. Some key points: - Glenmark ranks 9th in the drugs and pharmaceuticals industry in India in terms of sales revenues for 2019-20. - It has healthy operating and net margins of 19.7% and 18.3% respectively for the year ending March 2020. - Glenmark has a low debt-equity ratio of 0.278 times and total borrowings of Rs. 36,698.7 million. - The stock is currently underperforming, trading below its short, medium and long-term moving averages. Institutional investor holdings

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd

    Glenmark Pharmaceuticals LTD

    Uploaded by

    Harshit Kumar Singh
    73 views3 pages
    Glenmark Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company listed on both the Bombay Stock Exchange and National Stock Exchange. Some key points: - Glenmark ranks 9th in the drugs and pharmaceuticals industry in India in terms of sales revenues for 2019-20. - It has healthy operating and net margins of 19.7% and 18.3% respectively for the year ending March 2020. - Glenmark has a low debt-equity ratio of 0.278 times and total borrowings of Rs. 36,698.7 million. - The stock is currently underperforming, trading below its short, medium and long-term moving averages. Institutional investor holdings

    Original Title

    Glenmark Pharmaceuticals Ltd

    Copyright

    © © All Rights Reserved

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Glenmark Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company listed on both the Bombay Stock Exchange and National Stock Exchange. Some key points: - Glenmark ranks 9th in the drugs and pharmaceuticals industry in India in terms of sales revenues for 2019-20. - It has healthy operating and net margins of 19.7% and 18.3% respectively for the year ending March 2020. - Glenmark has a low debt-equity ratio of 0.278 times and total borrowings of Rs. 36,698.7 million. - The stock is currently underperforming, trading below its short, medium and long-term moving averages. Institutional investor holdings

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    73 views3 pages

    Glenmark Pharmaceuticals LTD

    Uploaded by

    Harshit Kumar Singh
    Glenmark Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company listed on both the Bombay Stock Exchange and National Stock Exchange. Some key points: - Glenmark ranks 9th in the drugs and pharmaceuticals industry in India in terms of sales revenues for 2019-20. - It has healthy operating and net margins of 19.7% and 18.3% respectively for the year ending March 2020. - Glenmark has a low debt-equity ratio of 0.278 times and total borrowings of Rs. 36,698.7 million. - The stock is currently underperforming, trading below its short, medium and long-term moving averages. Institutional investor holdings

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    of 3

    Business Simulation Game

    Group Id - II-6

    Glenmark Pharmaceuticals Ltd.

    Name Roll Number

    Nikhil Gupta 19BM63039

    Harshit Kumar Singh 19BM63058


    About company:
    Glenmark Pharmaceuticals is listed on both, the Bombay Stock Exchange (BSE) as well as on the National Stock
    Exchange (NSE). The company's shares were first traded on the BSE and NSE on 10 February 2000

    Sector:
    • Glenmark Pharmaceuticals ranks 9th in the Drugs & pharmaceuticals industry in terms of sales revenues in the year 2019-20
    • The company earned an operating margin of 19.7 per cent and a net margin of 18.3 per cent during the year ended 31 March 2020
    • Glenmark Pharmaceuticals is a low leveraged company with a debt-equity ratio of 0.278 times on the back of a total borrowing of Rs.36,698.7
    million
    Margin Ratios
    Financials: 25

    20
    Revenue 5.8%
    15
    Net Profit -11.2%
    10
    Operating Profit -5.9% 5

    0
    Mar-20 Mar-19 Mar-18 Mar-17 Mar-16
    • Bearish Momentum - Below short, medium and long-term Moving Averages
    Gross Profit Margin (%) Operating Margin (%)
    • 137.13% away from 52 week low Net Profit Margin (%)
    • 21.38% away from 52 week high
    • Underperformer - Glenmark Pharma down by -3.04% v/s NIFTY 50 down by -1.38% in last 1 month
    Industry Comparison: Return on Equity (%) Asset Turnover Ratio (%)
    78
    30
    • Trailing twelve months PE Ratio - Below industry Median 25 76
    • Market Cap - High in industry 20
    74
    15
    • Price to Book Ratio - Above industry Median 10 72
    5
    • TTM PEG Ratio - Above industry Median 0
    70
    Mar-20 Mar-19 Mar-18 Mar-17 Mar-16
    68
    Mar-20 Mar-19 Mar-18 Mar-17 Mar-16

    Return on Equity (%) Asset Turnover Ratio (%)

    Inference:
    • There was a logarithmic increase in shareholding pattern of FIIs from
    Mar ‘01 till Jun ’11. And in the period Dec’ 14 to Dec ‘20 public shares increased
    while there was no change in promoter equity
    • Institutional Investors have increased holdings from 30.25% to 35.91% in
    Dec 2020 qtr.

    You might also like